PURPOSE: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), an initiative coordinated by the European Medicines Agency, aims to build capacity for and increase trust in post-authorisation studies to further support medicine decision making. METHODS: ENCePP seeks to promote and support high standards throughout the post-authorisation research process based on robust methodologies, transparency and scientific independence. RESULTS: ENCePP provides a point of access to researchers for industry, academia and regulatory authorities seeking collaboration for the conduct of post-authorisation studies. As of 30 November 2011, the network consisted of 98 research centres, 13 networks and 18 data sources, mostly academic and publicly funded institutions but also data source providers and contract research organisations with expertise in the conduct of post-authorisation studies. All are listed in the free, public and fully searchable electronic Database of Research Resources. A guide and a checklist on methodological standards have been published; the concept of an 'ENCePP study', including a Code of Conduct, introduced; and an electronic register of studies have been launched. CONCLUSION: It is envisaged that application of the ENCePP study concept will result in an increase in trust in post-authorisation studies of medicines. The register of studies will allow for ready access to study protocols and results, thereby enhancing transparency and facilitating review. Through the network, standards, transparency and clarity of relationships, ENCePP is expected to add to the European Union capacity to conduct robust post-authorisation studies, thereby benefiting public health.
PURPOSE: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), an initiative coordinated by the European Medicines Agency, aims to build capacity for and increase trust in post-authorisation studies to further support medicine decision making. METHODS: ENCePP seeks to promote and support high standards throughout the post-authorisation research process based on robust methodologies, transparency and scientific independence. RESULTS: ENCePP provides a point of access to researchers for industry, academia and regulatory authorities seeking collaboration for the conduct of post-authorisation studies. As of 30 November 2011, the network consisted of 98 research centres, 13 networks and 18 data sources, mostly academic and publicly funded institutions but also data source providers and contract research organisations with expertise in the conduct of post-authorisation studies. All are listed in the free, public and fully searchable electronic Database of Research Resources. A guide and a checklist on methodological standards have been published; the concept of an 'ENCePP study', including a Code of Conduct, introduced; and an electronic register of studies have been launched. CONCLUSION: It is envisaged that application of the ENCePP study concept will result in an increase in trust in post-authorisation studies of medicines. The register of studies will allow for ready access to study protocols and results, thereby enhancing transparency and facilitating review. Through the network, standards, transparency and clarity of relationships, ENCePP is expected to add to the European Union capacity to conduct robust post-authorisation studies, thereby benefiting public health.
Authors: Rosa Gini; Xavier Fournie; Helen Dolk; Xavier Kurz; Patrice Verpillat; François Simondon; Valerie Strassmann; Kathi Apostolidis; Thomas Goedecke Journal: Pharmacoepidemiol Drug Saf Date: 2019-03-05 Impact factor: 2.890
Authors: M Sanni Ali; Daniel Prieto-Alhambra; Luciane Cruz Lopes; Dandara Ramos; Nivea Bispo; Maria Y Ichihara; Julia M Pescarini; Elizabeth Williamson; Rosemeire L Fiaccone; Mauricio L Barreto; Liam Smeeth Journal: Front Pharmacol Date: 2019-09-18 Impact factor: 5.810
Authors: Jeffrey S Brown; Kenneth R Petronis; Andrew Bate; Fang Zhang; Inna Dashevsky; Martin Kulldorff; Taliser R Avery; Robert L Davis; K Arnold Chan; Susan E Andrade; Denise Boudreau; Margaret J Gunter; Lisa Herrinton; Pamala A Pawloski; Marsha A Raebel; Douglas Roblin; David Smith; Robert Reynolds Journal: Pharmaceutics Date: 2013-03-14 Impact factor: 6.321
Authors: Jaco Voorham; Nicolas Roche; Hicham Benhaddi; Marianka van der Tol; Victoria Carter; Job F M van Boven; Leif Bjermer; Marc Miravitlles; David B Price Journal: BMJ Open Date: 2018-10-27 Impact factor: 2.692
Authors: Marjolein Engelkes; Esme J Baan; Maria A J de Ridder; Elisabeth Svensson; Daniel Prieto-Alhambra; Francesco Lapi; Carlo Giaquinto; Gino Picelli; Nada Boudiaf; Frank Albers; Lee A Evitt; Sarah Cockle; Eric Bradford; Melissa K Van Dyke; Robert Suruki; Peter Rijnbeek; Miriam C J M Sturkenboom; Hettie M Janssens; Katia M C Verhamme Journal: Pediatr Allergy Immunol Date: 2020-03-20 Impact factor: 6.377